WO2016012853A1 - Sugar compositions for tableting by direct compression - Google Patents

Sugar compositions for tableting by direct compression Download PDF

Info

Publication number
WO2016012853A1
WO2016012853A1 PCT/IB2015/001302 IB2015001302W WO2016012853A1 WO 2016012853 A1 WO2016012853 A1 WO 2016012853A1 IB 2015001302 W IB2015001302 W IB 2015001302W WO 2016012853 A1 WO2016012853 A1 WO 2016012853A1
Authority
WO
WIPO (PCT)
Prior art keywords
allulose
granules
directly compressible
tablet
compressible composition
Prior art date
Application number
PCT/IB2015/001302
Other languages
French (fr)
Inventor
Baptiste Boit
Pierre Lanos
Fabrice Buquet
Original Assignee
Roquette Freres
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/325,030 priority Critical patent/US20170208849A1/en
Priority to CA2955845A priority patent/CA2955845C/en
Priority to BR112017001000-3A priority patent/BR112017001000B1/en
Priority to EP15778703.7A priority patent/EP3171709A1/en
Priority to CN201580039976.2A priority patent/CN106659225B/en
Priority to MX2017000829A priority patent/MX2017000829A/en
Application filed by Roquette Freres filed Critical Roquette Freres
Priority to JP2017503616A priority patent/JP6731400B2/en
Priority to SG11201700445YA priority patent/SG11201700445YA/en
Priority to KR1020177000682A priority patent/KR102557664B1/en
Publication of WO2016012853A1 publication Critical patent/WO2016012853A1/en
Priority to US16/205,696 priority patent/US11350658B2/en
Priority to US17/720,656 priority patent/US11986002B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A23P10/25—Agglomeration or granulation by extrusion or by pressing, e.g. through small holes, through sieves or between surfaces
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to directly compressible compositions comprising more than 30 % by weight of allulose, and to tablets obtainable thereof.
  • Allulose is a hexoketose monosaccharide sweetener, which is a C-3 epimer of D- fructose and is rarely found in nature. It has 70 % relative sweetness but 0.3 % energy of sucrose, and is suggested as an ideal sucrose substitute for food products. It shows important physiological functions, such as blood glucose suppressive effect, reactive oxygen species scavenging activity, and neuroprotective effect. It also improves the gelling behavior and produces good flavor during food process.
  • a non-cariogenic sweetener with a major component of allulose has been reported in literature to offer health benefits relevant to weight management and obesity related illnesses (i.e. type II diabetes, metabolic disorders).
  • tablettes based on allulose, i.e., tablets comprising great amount of allulose, for use as a sweetener with health related benefits in confectionary products as well as nutritional and dietary supplement.
  • Human or vetenary pharmaceutical solid dosage form could also take advantages of such excipient.
  • the direct compression techniques enable the manufacture of tablets containing a precise amount of (active) ingredients, at high speed and at relatively low cost.
  • Direct compression consists in strongly compressing a powder into a die using a punch, so as to impart thereto the form of a tablet.
  • the high pressure applied allows aggregation of the molecules of the powder which produces a solid tablet.
  • powders include various ingredients, usually: - Diluents, also called “direct compression excipients” for the reason that they are the major compounds in the tablets and are responsible for the flow properties and compressibility of the powder to be compressed;
  • glidants whose role is to promote the flow of the powder within the equipment used for tableting; - pH stabilizing agents, colorants, flavors, surfactants.
  • Direct compression excipients are anhydrous lactose, cellulose and microcrystalline cellulose (MCC).
  • MMC microcrystalline cellulose
  • Direct compression excipients are the major ingredients in these compositions, as their role and their quantities are of importance in these compositions. They must be in large amounts to allow the obtaining of a solid dosage form.
  • the inventors prepared allulose capable of acting as a direct compression excipient, and as a result, that can be introduced in significant amounts in tablets.
  • the allulose according to the invention can advantageously fill both roles of sweetener and direct compression excipient.
  • allulose is not naturally compressible; meaning that allulose obtained by natural crystallization in water is not compressible. It lacks flow, cohesion or lubricating properties necessary for the production of tablets by direct compression.
  • the allulose developed by the inventors is in the form of granules, is compressible, and allows the preparation of tablets having hardness greater than 50 N.
  • the invention thus first relates to granules of allulose which are compressible in the sole presence of a lubricant, to form a tablet having a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1 .35 g/ml ⁇ 0.02 g/ml, a cylindrical shape with convex faces with a radius of curvature of 13 mm, whose hardness is greater than 50 N.
  • the present invention also relates to the use of granules of allulose according to the invention as a direct compression excipient in a directly compressible composition.
  • the present invention also relates to a directly compressible composition comprising the granules of allulose according to the invention.
  • the present invention also relates to a method for the manufacture of granules of allulose according to the invention, comprising: a step (a) of preparing a granulation liquid comprising allulose;
  • step (b) of granulating powdery allulose by applying the granulation liquid obtained in step (a) onto moving powdery allulose;
  • step (c) preferably simultaneous with step (b), of drying the granules obtained in step (b); an optional step (c') of maturation of the granules obtained in step (c);
  • the present invention further relates to a method for the manufacture of a tablet, comprising the steps of: providing a directly compressible composition according to the invention; followed by directly compressing said composition to form the tablet.
  • the present invention finally relates to a tablet composed of a directly compressible composition according to the invention, or obtained by the method for the manufacture of a tablet according to the invention.
  • compositions based on allulose, suitable for direct compression were obtained.
  • These directly compressible compositions allowed the preparation of tablets having hardness greater than 50 N. They comprised 99 % by weight of allulose, and no other direct compression excipient was required to obtain these results.
  • This allulose was obtained through a process of granulation that can be advantageously carried out by solely using water and allulose.
  • Granulation refers to the act or process in which primary powder particles are made to bind each other to form multiparticulate agglomerates called granules. It is the process of collecting particles together by creating bonds between them.
  • the two principal types of granulation technologies are wet granulation and dry granulation.
  • granules are formed by the addition of a granulation liquid onto a powder bed which is under the influence of an impeller (in a High or Low shear granulator), screws (in a twin screw granulator), a rotating device (for instance a rotating pan or a rotating drum), or even preferably, air (in a fluidized bed granulator or in a spray-drier).
  • the agitation and the wetting of the primary powder along the system results in the aggregation of the particles composing said primary powder to produce wet granules.
  • the granulation liquid is removed by drying.
  • the granulation liquid can be water-based or solvent-based. Typical solvents include water, ethanol and isopropanol either alone or in combination.
  • the granulation liquid mixed into the powders can form bonds between powder particles that are strong enough to lock them together. However, once the liquid dries, the powders usually fall apart.
  • Granulation process thus can be very complex depending on the characteristics of the powders, and the final objective.
  • the liquid is not strong enough to create and hold a bond.
  • one or more binders are required.
  • co-processing has been the most widely explored and commercially utilized method for the preparation of granules. It consists in combining through an appropriate process, the material to be granulated with one or more established other excipient, in particular binders.
  • the one or more binders to be selected will strongly depend on the material to be made compressible, and to the granulation process used. Depending on the method, the one or more binders will be introduced at different time during the process. It can be introduced dissolved in suitable solvent or in the form of a powder that will dissolve in the granulation liquid during the process.
  • binders are povidone, microcrystalline cellulose (MCC), carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPMC), starch derivatives like maltodextrins, acacia gum, tragacanth gum, gelatin.
  • Povidone which is a polyvinyl pyrrolidone (PVP)
  • PVP polyvinyl pyrrolidone
  • the use of a binder is not sufficient, and the powder needs to be pre-treated before to be granulated, typically by undergoing a step of spray-drying.
  • the inventors found that the compressible granules of allulose according to the invention could be obtained through particular process of wet granulation, by using allulose itself as a binder.
  • the granulation liquid is advantageously water-based, so has the advantage of being safe to deal with.
  • tablets comprising significant amounts of allulose, which can be greater than 30 % by weight relative to the total weight of the tablet, typically of between 90 and 99 %.
  • Allulose can advantageously play both role of direct compression excipient and sweetener in the compositions of the present application.
  • the granules of allulose according to the invention are particularly advantageous for both manufacture of suckable and chewable sweet tablets. Indeed, the tablets obtained out of the granules of allulose according to the invention exhibit excellent taste and texture, as compared to the sweet tablets of prior art, in particular as compared to the tablets made out of directly compressible sweet sugar or sugar alcohol of prior art. These tablets exhibit smooth sensation in the mouth when sucking, with no sticking and no gritty sensation, as well as pleasant chewable texture.
  • Granules of allulose according to the invention are compressible in the sole presence of a lubricant, to form a tablet having a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1 .35 g/ml ⁇ 0.02 g/ml, a cylindrical shape with convex faces with a radius of curvature of 13 mm, whose hardness is greater than 50 N, preferably greater than 60 N, preferably greater than 70 N, preferably greater than 80 N, preferably greater than 90 N, preferably greater than 100 N, even more preferably greater than 1 10 N.
  • the material to be compressed can be for instance composed of 99.0 % by weight of said material and 1 .0 % of lubricant, usually magnesium stearate.
  • the tablet can be formed by means of a single punch press, for instance like the one disclosed in “Procedure 1 " hereinafter in the Examples.
  • the hardness can be evaluated by the person skilled in the art on a hardness tester.
  • An example of such hardness tester is disclosed in "Procedure 1" described hereinafter in the Examples.
  • the value given in newtons usually corresponds to a mean value from 10 measurements.
  • the hardness is lower than 800 N, even lower than 400 N, even lower than 300 N, even lower than 200 N, even lower than 150 N.
  • the granules of allulose according to the invention preferably has mean volume diameter D 4,3 between 100 and 1000 ⁇ , preferably between 150 and 800 ⁇ and more preferably between 200 and 500 ⁇ .
  • the mean volume diameter D 4,3 can be determined by the person skilled in the art on a LASER diffraction granulometer type LS 230 from the company BECKMAN- COULTER, equipped with its powder dispersion module (dry method), following the manufacturer's technical manual and specifications.
  • the measurement range of the LASER diffraction granulometer type LS 230 is from 0.04 ⁇ to 2000 ⁇ .
  • the operating conditions of hopper screw speed and intensity of vibration of the dispersion channel are determined in such a way that the optical concentration is between 4% and 12%, ideally 8%.
  • the granules of allulose according to the invention can be used as a direct compression excipient in a directly compressible composition.
  • directly compressible composition means a powdery composition suitable, per se, for the manufacture of tablets by direct compression. This composition always comprises a direct compression excipient or a mixture of direct compression excipients. Such composition allows the manufacture of tablets of sufficient hardness, and of satisfying appearance.
  • the granules of allulose of the invention are further used as a sweetener, preferably as a low-calorie sweetener, i.e.
  • sweetener having a relative sweetness, as compared to sucrose, of between 0.5 and 1 .0, preferably of between 0.6 and 0.8, typically of 0.7.
  • the granules of allulose of the invention are further used as a health ingredient having physiological functions, such as blood glucose suppressive effect, reactive oxygen species scavenging activity, and/or neuroprotective effect.
  • the directly compressible compositions according to the invention can comprise significant amounts of allulose, notably without requiring the adding of other direct compression excipients.
  • granules of allulose preferably represent at least 30 % of the directly compressible composition, preferably at least 40 %, preferably at least 50 %, preferably at least 60 %, preferably at least 70 %, preferably at least 80 %, preferably at least 90 %, typically between 90 and 99 %, even between 95 and 99 %, said percentage being expressed in dry weight, with respect to the total dry weight of said directly compressible composition.
  • the directly compressible compositions according to the invention comprises no more than 60 % of direct compression excipients other than the granules of allulose according to the invention, preferably no more than 50 %, preferably no more than 40 %, preferably no more than 30 %, preferably no more than 20 %, preferably no more than 10 %, preferably no more than 5 %, more preferably no more than 2 %, and most preferably 0 %, said percentage being expressed in dry weight, with respect to the total dry weight of said directly compressible composition.
  • step (b) of granulating powdery allulose by applying the granulation liquid obtained in step (a) onto moving powdery allulose;
  • step (c) preferably simultaneous with step (b), of drying the granules obtained in step (b);
  • step (a) simply consists in dissolving powdery allulose into water, to obtain an aqueous solution of allulose.
  • Powdery allulose can be, for instance, individual crystals, classically obtained by crystallization from a solvent such as water or a mixture of water and ethanol, preferably water alone.
  • Powdery allulose can also be composed of, or can also comprise, the granules obtained in step (c) or (c'), which are preferably grinded before undergoing step (b).
  • Step (a) is preferably performed at a temperature which allows good dissolving of allulose into water. It is preferably performed at ambient temperature as allulose is very soluble in water (about 225 g per 100 ml water at 20°C).
  • a heating will be required for the preparation of a granulation liquid comprising higher concentrations of allulose.
  • the allulose will be dissolved in water heated from 85 °C to 100 °C.
  • the granulation liquid is applied by means of a spraying system, for instance by using one or more spraying nozzle(s). It is preferably applied in the form of fine droplets.
  • the quality of the contact between the granulation liquid and the powdery allulose during step (b) notably depends on the mean used to move the powdery allulose. This can be performed by subjecting the powder to the influence of an impeller (in a High or Low shear granulator), screws (in a twin screw granulator), a rotating device (for instance a rotating pan or a rotating drum), or even preferably, air (in a fluidized bed granulator or in a spray-drier).
  • the drying performed in step (c) is preferably performed concomitantly to the granulation step (b), by way of a granulator using air for granulation and for drying like spray-driers or fluidized bed granulators and dryers.
  • the method for the manufacture of granules of allulose according to the invention is preferably a continuous process using in particular a mixer-granulator, a continuous fluid bed granulator, or a spray-dryer.
  • the continuous process preferably includes the recycling of the granules obtained in step (c) or (c').
  • the granules are preferably grinded before undergoing step (b).
  • the amount of recycled granules can be adapted so as to optimize the crystallization of allulose, to prevent the excessive formation of amorphous allulose.
  • the ratio by weight of granulation liquid to the recycled granules is thus preferably of between 1 :2 and 1 :15, preferably of between 1 :4 and 1 :10.
  • the continuous process can be performed in an spray-dryer preferably equipped with a high pressure spray-drying nozzle, for instance of MSD-type, which preferably comprises the recycling of particles in the drying chamber.
  • Granulation may be carried out using, for example, a mixer-granulator operating batchwise, semi-continuously or continuously such as the vertical FLEXOMIX marketed by SCHUGI, a device of the DRIAM or DUMOULIN type, or the horizontal CB marketed by LODIGE into which is introduced, by way of a weight feeder, the starting powdery allulose to be granulated continuously and the granulation liquid by way of a volumetric feeder.
  • the starting powdery allulose and the granulation solution are very intimately mixed in the mixer-granulator fitted with a shaft with knives arranged in the form of blades, and a system of spraying liquids by way of injection nozzles.
  • satisfactory dispersion of the constituents and agglomeration of the particles of the starting powdery allulose are carried out by high speed stirring, i.e. at a value at least equal to 1000 rpm, preferably at least equal to 3500 rpm.
  • the granules formed are discharged continuously into a dryer-ageing device. Discharge takes place preferably by gravity in the case of said vertical granulator, and by thrust by way of the shaft of rotating knives if the horizontal granulator is used.
  • This second drying-ageing step at the outlet of the mixer-granulator makes it possible to remove, if necessary, all or part of the water originating from the binder such that crystallization and stabilization take place after the prior granulation step.
  • the dryer-ageing device may be, for example, a fluidized bed dryer-ageing device or a rotary ageing drum.
  • the allulose according to the invention is obtained after cooling and optionally sieving.
  • the fine particles may be recycled directly to the start of granulation, and the coarse particles may be ground and recycled to the start of sieving.
  • Granulation can be performed in a high shear granulator, using a high speed propeller and a chopper to avoid too big lumps to be created.
  • high shear granulators are very common in the pharmaceutical industry and manufactured by well-known suppliers (GLATT, DIOSNA, IMA and the like).
  • GLATT, DIOSNA, IMA and the like Such high shear granulators are very common in the pharmaceutical industry and manufactured by well-known suppliers (GLATT, DIOSNA, IMA and the like).
  • the drying step (c) has to be done after the granulation step (b).
  • fluidized bed granulators GLATT, GEA and the like
  • step (a) This process used to be a batch one but modern fluid bed granulators have been designed to run continuously. Such continuous equipment is preferred.
  • step (a) the starting allulose is in general the same as the one used in the moving powdery allulose.
  • Optional step (c') can be performed to allow granules to further crystallization and stabilization at a controlled temperature.
  • This step (c') is preferably performed in a fluid bed or in a rotary drum.
  • the granules of allulose according to the invention may comprise other ingredients, as long as it does not negatively affect the desired properties of the granules.
  • the other ingredients are generally introduced in the process of manufacture of granules of allulose according to the invention, via the granulation liquid or via the moving powdery allulose.
  • Such Other ingredients' can be without limitation: binders such as polyvinyl pyrrolidone, CMC, HPMC, cellulosic derivatives, acacia gum, gelatin, starch derivatives like maltodextrins, tragacanth gum and the like; food additives, colorants, glidants, lubricants, pharmaceutical, nutraceutical or veterinary active ingredients, preservatives, stabilizing ingredients;
  • the granules preferably contain substantially no binders, other than allulose.
  • the total amount of Other ingredients' will be lower than 80 %, preferably lower than 40 %, preferably lower than 10 %, preferably lower than 5 %, most preferably equal to 0 %, said percentage being expressed in dry weight, with respect to the total dry weight of said granules.
  • ingredients do not mean to include impurities, like those resulting from the synthesis of allulose, typically residual fructose.
  • the allulose such as defined in the present invention generally has purity between 95.0 and 99.9 %, said percentage being expressed in dry weight of allulose with respect to the total dry weight of said allulose
  • the purity can in particular be determined by the person skilled in the art by using HPLC method with calcium column.
  • tablette means any solid edible preparation, which is obtained by direct compression.
  • These tablets can be in the form of suckable tablets like mints, or in the form of soft or hard chewable tablets. They can be normal or multi layers tablets. They can be used as a nutritional or dietary supplement, or as a pharmaceutical, and can be intended for humans, adults or children, or to animals.
  • the tablet is a sweet tablet, having calorific value lower than 5 kcal/g, preferably lower than 4 kcal/g, preferably lower than 3 kcal/g, preferably lower than 2 kcal/g, even more preferably lower than 1 kcal/g.
  • It preferably has a relative sweetness, as compared to sucrose, of between 0.5 and 1 .0, preferably of between 0.6 and 0.8, for example of 0.7.
  • the tablet according to the invention has hardness greater than 50 N, preferably greater than 60 N, preferably greater than 70 N, preferably greater than 80 N, preferably greater than 90 N, preferably greater than 100 N, preferably greater than 1 10 N.
  • the hardness of the tablet is lower than 800 N, even lower than 700 N, even lower than 600 N, even lower than 500 N, even lower than 400 N, even lower than 300 N, even lower than 200 N, even lower than 150 N.
  • the tablets according to the invention can be coated, notably by regular spray-drying of a film-forming composition onto a moving bed of tablets.
  • the coating layer in general, will not exceed 5 % in weight of the coated tablet.
  • the tablets may also be coated with sugars or polyols, using a "sugar-coating" process to form a frosting or a soft or hard coating, depending on the amount of powders or the coating process used.
  • the directly compressible compositions and the tablets according to the invention generally comprise other ingredients.
  • Such Other ingredients' can be without limitation: direct compression excipient other than allulose, for example (i) directly compressible sugar alcohols like directly compressible forms of sorbitol, mannitol, maltitol, xylitol, isomalt, lactitol, erythritol, (ii) directly compressible sugars like directly compressible forms of sucrose, dextrose, dextrates, lactose, (iii) microcrystalline cellulose, (iv) directly compressible minerals; however it is reminded that the composition for tableting by direct compression according to the present invention preferably comprises no more than 60 %, and most preferably 0 % of direct compression excipient other than allulose;
  • dispersants or disintegrants for example sodium starch glycolate, crosslinked carboxymethyl cellulose, crosslinked polyvinylpyrrolidone, starches;
  • granulating agents such as polyvinyl pyrrolidone, acacia gum, dextrose, gelatin, maltodextrin, starch and starch derivatives, tragacanth gum and the like;
  • - lubricants for example magnesium stearate, stearic acid, sodium stearyl fumarate, sucroesters;
  • flavoring agents for instance mint, honey, essential oils such as citrus, peppermint or eucalyptus, fruit flavors, acidulants such as citric acid, acidity regulators;
  • glidants for example silica dioxide
  • ant sticking agent for example talcum
  • compositions composed of 99.0 % by weight of the material to be tested as a direct compression excipient and 1 .0 % by weight of magnesium stearate were first prepared.
  • Tablets were prepared out from these compositions, by means of the single punch laboratory press FROGERAIS AM (SVIAC, Anthony, France).
  • These tablets had a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1 .35 g/ml ⁇ 0.02 g/ml, and a cylindrical shape with convex faces with a radius of curvature of 13 mm.
  • the inventors measured the hardness of the tablets thus obtained on an ERWEKA TBH 30 GMD hardness tester (ERWEKA, Heusenstamm, Germany). The value given in Newtons corresponds to a mean value from 1 0 measurements.
  • Granules of allulose were prepared in a fluid bed granulator Strea-1 (Aeromatic_Fielder / GEA - Bubendorf Switzerland).
  • a solution of allulose is prepared by dissolving 25 g of allulose in 125 ml of water. This solution is sprayed on 300 g of powdery allulose fluidized in the fluid bed granulator.
  • the allulose powder used has a mean diameter of 85 ⁇ .
  • the fluidizing air entrance is at 60 °C and the outlet air at 35°C. This solution is added during 1 5 minutes (spraying speed about 1 0 ml per minute).
  • the drying air at 60 °C is pursued about 30 minutes after the end of the spraying so that the powder is sufficiently dried.
  • the granules obtained are sieved between 100 ⁇ and 1000 ⁇ to remove the fine and coarse particles, to give granules [i-A].
  • Granules of allulose of a few millimeters were formed and continuously discharged out of rotating pan while the volume in the pan remains at constant.
  • the granules were dried and maturated at forced-air circulation oven at 75 ⁇ for 2 hours and conditioned at ambient temperature for 4 hours.
  • the granules were then grinded and sieved at desired particle size of between 100 and 1000 ⁇ to give granules [i-B].
  • the inventors succeeded for the first time in obtaining directly compressible allulose, allowing the preparation of tablets having hardness greater than 50 N, in the sole presence of a lubricant, in particular in the present case, from compositions composed of 99.0 % by weight of granules of allulose according to the invention and 1 .0 % by weight of magnesium stearate.
  • the tablets thus obtained exhibited excellent taste and texture. They showed particularly smooth sensation in the mouth when sucking, with no sticking and no gritty sensation, as well as particularly pleasant chewable texture.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Seasonings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to directly compressible compositions comprising more than 30 % by weight of allulose, and to tablets obtainable thereof.

Description

Sugar compositions for tabletinq by direct compression
The present invention relates to directly compressible compositions comprising more than 30 % by weight of allulose, and to tablets obtainable thereof.
PRIOR ART Allulose is a hexoketose monosaccharide sweetener, which is a C-3 epimer of D- fructose and is rarely found in nature. It has 70 % relative sweetness but 0.3 % energy of sucrose, and is suggested as an ideal sucrose substitute for food products. It shows important physiological functions, such as blood glucose suppressive effect, reactive oxygen species scavenging activity, and neuroprotective effect. It also improves the gelling behavior and produces good flavor during food process.
A non-cariogenic sweetener with a major component of allulose has been reported in literature to offer health benefits relevant to weight management and obesity related illnesses (i.e. type II diabetes, metabolic disorders).
Allulose has already been used as a sweetener in food and drink formulations, (see for instance patent applications EP 2 156 751 A1 , US 2012/076908 A1 and US 2009/304891 A1 ), but could not be found in the form of tablets in the prior art.
However there would be a great advantage to have tablets based on allulose, i.e., tablets comprising great amount of allulose, for use as a sweetener with health related benefits in confectionary products as well as nutritional and dietary supplement. Human or vetenary pharmaceutical solid dosage form (tablets) could also take advantages of such excipient.
The direct compression techniques enable the manufacture of tablets containing a precise amount of (active) ingredients, at high speed and at relatively low cost.
Direct compression consists in strongly compressing a powder into a die using a punch, so as to impart thereto the form of a tablet. The high pressure applied allows aggregation of the molecules of the powder which produces a solid tablet.
These powders include various ingredients, usually: - Diluents, also called "direct compression excipients" for the reason that they are the major compounds in the tablets and are responsible for the flow properties and compressibility of the powder to be compressed;
- (super-) Disintegrants, whose aim is to facilitate tablet disintegration in aqueous media, to promote the release of active ingredients, for instance when the tablet is ingested;
- lubricants, whose role is to enable the ejection of newly formed tablets from their matrices;
- glidants, whose role is to promote the flow of the powder within the equipment used for tableting; - pH stabilizing agents, colorants, flavors, surfactants.
Commonly used direct compression excipients are anhydrous lactose, cellulose and microcrystalline cellulose (MCC). Direct compression excipients are the major ingredients in these compositions, as their role and their quantities are of importance in these compositions. They must be in large amounts to allow the obtaining of a solid dosage form.
As a result, only a little amount of other material can usually be introduced in tablets. This is why tablets comprising great amounts of allulose could not be found in the prior art.
However, the inventors succeeded in obtaining tablets which can comprise more than 30 % by weight of allulose.
To do so, the inventors prepared allulose capable of acting as a direct compression excipient, and as a result, that can be introduced in significant amounts in tablets. The allulose according to the invention can advantageously fill both roles of sweetener and direct compression excipient. Indeed, allulose is not naturally compressible; meaning that allulose obtained by natural crystallization in water is not compressible. It lacks flow, cohesion or lubricating properties necessary for the production of tablets by direct compression. The allulose developed by the inventors is in the form of granules, is compressible, and allows the preparation of tablets having hardness greater than 50 N.
There was no hint in the prior art suggesting allulose acting as a direct compression excipient. A fortiori, there was no hint in the prior art suggesting that this allulose needed to be in the form of granules.
OBJECT
It was thus an object of the present invention to provide directly compressible compositions comprising significant amounts of allulose.
It was another object of the invention to provide tablets based on allulose, i.e. tablets exhibiting high amounts of allulose, and at the same time, satisfying hardness.
BRIEF DESCRIPTION OF THE INVENTION
The invention thus first relates to granules of allulose which are compressible in the sole presence of a lubricant, to form a tablet having a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1 .35 g/ml ± 0.02 g/ml, a cylindrical shape with convex faces with a radius of curvature of 13 mm, whose hardness is greater than 50 N.
The present invention also relates to the use of granules of allulose according to the invention as a direct compression excipient in a directly compressible composition.
The present invention also relates to a directly compressible composition comprising the granules of allulose according to the invention. The present invention also relates to a method for the manufacture of granules of allulose according to the invention, comprising: a step (a) of preparing a granulation liquid comprising allulose;
a step (b) of granulating powdery allulose, by applying the granulation liquid obtained in step (a) onto moving powdery allulose;
- a step (c), preferably simultaneous with step (b), of drying the granules obtained in step (b); an optional step (c') of maturation of the granules obtained in step (c);
a step (d) of recovering the granules obtained in step (c) or (c').
The present invention further relates to a method for the manufacture of a tablet, comprising the steps of: providing a directly compressible composition according to the invention; followed by directly compressing said composition to form the tablet.
The present invention finally relates to a tablet composed of a directly compressible composition according to the invention, or obtained by the method for the manufacture of a tablet according to the invention.
DETAILED DESCRIPTION OF THE INVENTION The inventors succeeded in obtaining compositions based on allulose, suitable for direct compression, as evidenced in Example 1 . These directly compressible compositions allowed the preparation of tablets having hardness greater than 50 N. They comprised 99 % by weight of allulose, and no other direct compression excipient was required to obtain these results. This allulose was obtained through a process of granulation that can be advantageously carried out by solely using water and allulose.
Granulation refers to the act or process in which primary powder particles are made to bind each other to form multiparticulate agglomerates called granules. It is the process of collecting particles together by creating bonds between them. The two principal types of granulation technologies are wet granulation and dry granulation.
In wet granulation, granules are formed by the addition of a granulation liquid onto a powder bed which is under the influence of an impeller (in a High or Low shear granulator), screws (in a twin screw granulator), a rotating device (for instance a rotating pan or a rotating drum), or even preferably, air (in a fluidized bed granulator or in a spray-drier). The agitation and the wetting of the primary powder along the system results in the aggregation of the particles composing said primary powder to produce wet granules. The granulation liquid is removed by drying. The granulation liquid can be water-based or solvent-based. Typical solvents include water, ethanol and isopropanol either alone or in combination.
The granulation liquid mixed into the powders can form bonds between powder particles that are strong enough to lock them together. However, once the liquid dries, the powders usually fall apart.
Granulation process thus can be very complex depending on the characteristics of the powders, and the final objective.
In general the liquid is not strong enough to create and hold a bond. In such instances, one or more binders are required. To this end co-processing has been the most widely explored and commercially utilized method for the preparation of granules. It consists in combining through an appropriate process, the material to be granulated with one or more established other excipient, in particular binders.
The one or more binders to be selected will strongly depend on the material to be made compressible, and to the granulation process used. Depending on the method, the one or more binders will be introduced at different time during the process. It can be introduced dissolved in suitable solvent or in the form of a powder that will dissolve in the granulation liquid during the process.
Examples of binders are povidone, microcrystalline cellulose (MCC), carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPMC), starch derivatives like maltodextrins, acacia gum, tragacanth gum, gelatin.
Povidone, which is a polyvinyl pyrrolidone (PVP), is one of the most commonly used pharmaceutical binders in wet granulation processes. When PVP and a solvent are mixed with powders, PVP forms a bond with the powders during the process, and the solvent evaporates.
Sometimes, the use of a binder is not sufficient, and the powder needs to be pre-treated before to be granulated, typically by undergoing a step of spray-drying. Surprisingly, and as evidenced in Example 1 , the inventors found that the compressible granules of allulose according to the invention could be obtained through particular process of wet granulation, by using allulose itself as a binder.
That is to say, that allulose was turn into granules without the need of being co- processed.
Even more surprisingly, and advantageously, no pre-treatment of the powdery allulose was required to obtain such granules of allulose.
This means that not only the inventors were able for the first time to obtain a directly compressible allulose, but also in doing so, found that this was possible thanks to a particularly easy to carry out process. To be implemented, this process does not require excessive number of materials and of steps.
Moreover the granulation liquid is advantageously water-based, so has the advantage of being safe to deal with.
Thanks to the inventors, it is now possible to obtain tablets, comprising significant amounts of allulose, which can be greater than 30 % by weight relative to the total weight of the tablet, typically of between 90 and 99 %.
Allulose can advantageously play both role of direct compression excipient and sweetener in the compositions of the present application.
The granules of allulose according to the invention are particularly advantageous for both manufacture of suckable and chewable sweet tablets. Indeed, the tablets obtained out of the granules of allulose according to the invention exhibit excellent taste and texture, as compared to the sweet tablets of prior art, in particular as compared to the tablets made out of directly compressible sweet sugar or sugar alcohol of prior art. These tablets exhibit smooth sensation in the mouth when sucking, with no sticking and no gritty sensation, as well as pleasant chewable texture.
This was not possible before the present invention, because compressible allulose could not be found. If high amounts of allulose would have been used, the compositions obtained thereof would have been impossible to compress. Granules of allulose according to the invention are compressible in the sole presence of a lubricant, to form a tablet having a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1 .35 g/ml ± 0.02 g/ml, a cylindrical shape with convex faces with a radius of curvature of 13 mm, whose hardness is greater than 50 N, preferably greater than 60 N, preferably greater than 70 N, preferably greater than 80 N, preferably greater than 90 N, preferably greater than 100 N, even more preferably greater than 1 10 N.
In order to evaluate if a material is compressible and can allow forming tablets having the hardness complying with the invention, the person skilled in the art can adapt the nature and the amount of lubricant used. The material to be compressed can be for instance composed of 99.0 % by weight of said material and 1 .0 % of lubricant, usually magnesium stearate.
The tablet can be formed by means of a single punch press, for instance like the one disclosed in "Procedure 1 " hereinafter in the Examples.
The hardness can be evaluated by the person skilled in the art on a hardness tester. An example of such hardness tester is disclosed in "Procedure 1 " described hereinafter in the Examples. The value given in newtons usually corresponds to a mean value from 10 measurements.
In general, the hardness is lower than 800 N, even lower than 400 N, even lower than 300 N, even lower than 200 N, even lower than 150 N. The granules of allulose according to the invention preferably has mean volume diameter D 4,3 between 100 and 1000 μιτι, preferably between 150 and 800 μιτι and more preferably between 200 and 500 μιτι.
The mean volume diameter D 4,3 can be determined by the person skilled in the art on a LASER diffraction granulometer type LS 230 from the company BECKMAN- COULTER, equipped with its powder dispersion module (dry method), following the manufacturer's technical manual and specifications. The measurement range of the LASER diffraction granulometer type LS 230 is from 0.04 μιτι to 2000 μιτι. The operating conditions of hopper screw speed and intensity of vibration of the dispersion channel are determined in such a way that the optical concentration is between 4% and 12%, ideally 8%. The results are calculated in percentage by volume, and expressed in μιτι. Allulose used according to the invention can be in either the D- or L-configuration, however D-allulose is preferred in the present invention, because easier to obtain.
The granules of allulose according to the invention can be used as a direct compression excipient in a directly compressible composition. In the present invention, "directly compressible composition" means a powdery composition suitable, per se, for the manufacture of tablets by direct compression. This composition always comprises a direct compression excipient or a mixture of direct compression excipients. Such composition allows the manufacture of tablets of sufficient hardness, and of satisfying appearance. Preferably, the granules of allulose of the invention are further used as a sweetener, preferably as a low-calorie sweetener, i.e. for the manufacture of tablets having calorific value lower than 5 kcal/g, preferably lower than 4 kcal/g, preferably lower than 3 kcal/g, preferably lower than 2 kcal/g, even more preferably lower than 1 kcal/g.
It is preferably used as a sweetener having a relative sweetness, as compared to sucrose, of between 0.5 and 1 .0, preferably of between 0.6 and 0.8, typically of 0.7.
Preferably, the granules of allulose of the invention are further used as a health ingredient having physiological functions, such as blood glucose suppressive effect, reactive oxygen species scavenging activity, and/or neuroprotective effect.
It is another object of the present invention to provide a directly compressible composition, comprising the granules of allulose according to the invention.
Thanks to the granules of allulose according to the invention, the directly compressible compositions according to the invention can comprise significant amounts of allulose, notably without requiring the adding of other direct compression excipients.
In the directly compressible composition according to the invention, granules of allulose preferably represent at least 30 % of the directly compressible composition, preferably at least 40 %, preferably at least 50 %, preferably at least 60 %, preferably at least 70 %, preferably at least 80 %, preferably at least 90 %, typically between 90 and 99 %, even between 95 and 99 %, said percentage being expressed in dry weight, with respect to the total dry weight of said directly compressible composition. Preferably, the directly compressible compositions according to the invention comprises no more than 60 % of direct compression excipients other than the granules of allulose according to the invention, preferably no more than 50 %, preferably no more than 40 %, preferably no more than 30 %, preferably no more than 20 %, preferably no more than 10 %, preferably no more than 5 %, more preferably no more than 2 %, and most preferably 0 %, said percentage being expressed in dry weight, with respect to the total dry weight of said directly compressible composition.
It is another object of the present invention to provide a method for the manufacture of granules of allulose according to the invention, comprising: - a step (a) of preparing a granulation liquid comprising allulose;
a step (b) of granulating powdery allulose, by applying the granulation liquid obtained in step (a) onto moving powdery allulose;
a step (c), preferably simultaneous with step (b), of drying the granules obtained in step (b);
- an optional step (c') of maturation of the granules obtained in step (c);
a step (d) of recovering the granules obtained in step (c) or (c').
In general, step (a) simply consists in dissolving powdery allulose into water, to obtain an aqueous solution of allulose.
Powdery allulose can be, for instance, individual crystals, classically obtained by crystallization from a solvent such as water or a mixture of water and ethanol, preferably water alone.
Powdery allulose can also be composed of, or can also comprise, the granules obtained in step (c) or (c'), which are preferably grinded before undergoing step (b).
Step (a) is preferably performed at a temperature which allows good dissolving of allulose into water. It is preferably performed at ambient temperature as allulose is very soluble in water (about 225 g per 100 ml water at 20°C). For the preparation of a granulation liquid comprising higher concentrations of allulose, a heating will be required. Typically the allulose will be dissolved in water heated from 85 °C to 100 °C. Preferably, the granulation liquid is applied by means of a spraying system, for instance by using one or more spraying nozzle(s). It is preferably applied in the form of fine droplets.
The quality of the contact between the granulation liquid and the powdery allulose during step (b) notably depends on the mean used to move the powdery allulose. This can be performed by subjecting the powder to the influence of an impeller (in a High or Low shear granulator), screws (in a twin screw granulator), a rotating device (for instance a rotating pan or a rotating drum), or even preferably, air (in a fluidized bed granulator or in a spray-drier). The drying performed in step (c) is preferably performed concomitantly to the granulation step (b), by way of a granulator using air for granulation and for drying like spray-driers or fluidized bed granulators and dryers.
The method for the manufacture of granules of allulose according to the invention is preferably a continuous process using in particular a mixer-granulator, a continuous fluid bed granulator, or a spray-dryer.
The continuous process preferably includes the recycling of the granules obtained in step (c) or (c'). In this case, the granules are preferably grinded before undergoing step (b). The amount of recycled granules can be adapted so as to optimize the crystallization of allulose, to prevent the excessive formation of amorphous allulose. The ratio by weight of granulation liquid to the recycled granules is thus preferably of between 1 :2 and 1 :15, preferably of between 1 :4 and 1 :10.
The continuous process can be performed in an spray-dryer preferably equipped with a high pressure spray-drying nozzle, for instance of MSD-type, which preferably comprises the recycling of particles in the drying chamber. Granulation may be carried out using, for example, a mixer-granulator operating batchwise, semi-continuously or continuously such as the vertical FLEXOMIX marketed by SCHUGI, a device of the DRIAM or DUMOULIN type, or the horizontal CB marketed by LODIGE into which is introduced, by way of a weight feeder, the starting powdery allulose to be granulated continuously and the granulation liquid by way of a volumetric feeder. When using a SCHUGI vertical FLEXOMIX type, the starting powdery allulose and the granulation solution are very intimately mixed in the mixer-granulator fitted with a shaft with knives arranged in the form of blades, and a system of spraying liquids by way of injection nozzles. According to a preferred embodiment of the invention, satisfactory dispersion of the constituents and agglomeration of the particles of the starting powdery allulose are carried out by high speed stirring, i.e. at a value at least equal to 1000 rpm, preferably at least equal to 3500 rpm. At the outlet of the mixer-granulator, the granules formed are discharged continuously into a dryer-ageing device. Discharge takes place preferably by gravity in the case of said vertical granulator, and by thrust by way of the shaft of rotating knives if the horizontal granulator is used.
This second drying-ageing step at the outlet of the mixer-granulator makes it possible to remove, if necessary, all or part of the water originating from the binder such that crystallization and stabilization take place after the prior granulation step. The dryer-ageing device may be, for example, a fluidized bed dryer-ageing device or a rotary ageing drum. The allulose according to the invention is obtained after cooling and optionally sieving.
In this case, the fine particles may be recycled directly to the start of granulation, and the coarse particles may be ground and recycled to the start of sieving. Granulation can be performed in a high shear granulator, using a high speed propeller and a chopper to avoid too big lumps to be created. Such high shear granulators are very common in the pharmaceutical industry and manufactured by well-known suppliers (GLATT, DIOSNA, IMA and the like). Using such equipment the drying step (c) has to be done after the granulation step (b). On the opposite, fluidized bed granulators (GLATT, GEA and the like) enable to do granulation step (b) and drying step (c) concomitantly. This process used to be a batch one but modern fluid bed granulators have been designed to run continuously. Such continuous equipment is preferred. For step (a), and because this is more convenient, the starting allulose is in general the same as the one used in the moving powdery allulose.
Optional step (c') can be performed to allow granules to further crystallization and stabilization at a controlled temperature. This step (c') is preferably performed in a fluid bed or in a rotary drum.
The granules of allulose according to the invention may comprise other ingredients, as long as it does not negatively affect the desired properties of the granules.
When present, the other ingredients are generally introduced in the process of manufacture of granules of allulose according to the invention, via the granulation liquid or via the moving powdery allulose.
Such Other ingredients' can be without limitation: binders such as polyvinyl pyrrolidone, CMC, HPMC, cellulosic derivatives, acacia gum, gelatin, starch derivatives like maltodextrins, tragacanth gum and the like; food additives, colorants, glidants, lubricants, pharmaceutical, nutraceutical or veterinary active ingredients, preservatives, stabilizing ingredients;
or mixtures thereof.
However, to limit the number of materials used, and because it is not required to obtain a satisfactory direct compression excipient, the granules preferably contain substantially no binders, other than allulose. In general, the total amount of Other ingredients', will be lower than 80 %, preferably lower than 40 %, preferably lower than 10 %, preferably lower than 5 %, most preferably equal to 0 %, said percentage being expressed in dry weight, with respect to the total dry weight of said granules.
By Other ingredients' the inventors do not mean to include impurities, like those resulting from the synthesis of allulose, typically residual fructose.
In particular, the allulose such as defined in the present invention generally has purity between 95.0 and 99.9 %, said percentage being expressed in dry weight of allulose with respect to the total dry weight of said allulose The purity can in particular be determined by the person skilled in the art by using HPLC method with calcium column.
It is another object of the present invention to provide a method for the manufacture of a tablet, comprising the steps of: providing a directly compressible composition according to the invention; followed by directly compressing the composition to form the tablet.
It is another object of the present invention to provide a tablet, composed of the directly compressible composition according to the invention.
In the present invention, "tablet" means any solid edible preparation, which is obtained by direct compression. These tablets can be in the form of suckable tablets like mints, or in the form of soft or hard chewable tablets. They can be normal or multi layers tablets. They can be used as a nutritional or dietary supplement, or as a pharmaceutical, and can be intended for humans, adults or children, or to animals. Preferably the tablet is a sweet tablet, having calorific value lower than 5 kcal/g, preferably lower than 4 kcal/g, preferably lower than 3 kcal/g, preferably lower than 2 kcal/g, even more preferably lower than 1 kcal/g.
It preferably has a relative sweetness, as compared to sucrose, of between 0.5 and 1 .0, preferably of between 0.6 and 0.8, for example of 0.7.
Preferably, the tablet according to the invention has hardness greater than 50 N, preferably greater than 60 N, preferably greater than 70 N, preferably greater than 80 N, preferably greater than 90 N, preferably greater than 100 N, preferably greater than 1 10 N.
In general, the hardness of the tablet is lower than 800 N, even lower than 700 N, even lower than 600 N, even lower than 500 N, even lower than 400 N, even lower than 300 N, even lower than 200 N, even lower than 150 N. The tablets according to the invention can be coated, notably by regular spray-drying of a film-forming composition onto a moving bed of tablets. The coating layer in general, will not exceed 5 % in weight of the coated tablet. The tablets may also be coated with sugars or polyols, using a "sugar-coating" process to form a frosting or a soft or hard coating, depending on the amount of powders or the coating process used. The directly compressible compositions and the tablets according to the invention generally comprise other ingredients. Such Other ingredients' can be without limitation: direct compression excipient other than allulose, for example (i) directly compressible sugar alcohols like directly compressible forms of sorbitol, mannitol, maltitol, xylitol, isomalt, lactitol, erythritol, (ii) directly compressible sugars like directly compressible forms of sucrose, dextrose, dextrates, lactose, (iii) microcrystalline cellulose, (iv) directly compressible minerals; however it is reminded that the composition for tableting by direct compression according to the present invention preferably comprises no more than 60 %, and most preferably 0 % of direct compression excipient other than allulose;
dispersants or disintegrants, for example sodium starch glycolate, crosslinked carboxymethyl cellulose, crosslinked polyvinylpyrrolidone, starches;
granulating agents such as polyvinyl pyrrolidone, acacia gum, dextrose, gelatin, maltodextrin, starch and starch derivatives, tragacanth gum and the like;
- lubricants, for example magnesium stearate, stearic acid, sodium stearyl fumarate, sucroesters;
food additives, such as flavoring agents, for instance mint, honey, essential oils such as citrus, peppermint or eucalyptus, fruit flavors, acidulants such as citric acid, acidity regulators;
- colorants like mineral dyes, pigments or solubles colorants;
glidants (for example silica dioxide) or ant sticking agent (for example talcum);
pharmaceutical, nutraceutical or veterinary active substances;
and mixtures thereof.
The following Examples serve to illustrate the invention and should by no means be construed so as to limit the scope of the invention.
EXAMPLES
In the following examples, granules of allulose according to the invention were prepared and put into the form of tablets whose hardness was determined, according to the Procedure 1 described below. An allulose of prior art, obtained by crystallization in water, was used for comparison. Procedure 1 - Tablets preparation and hardness measurement
Compositions composed of 99.0 % by weight of the material to be tested as a direct compression excipient and 1 .0 % by weight of magnesium stearate were first prepared.
Tablets were prepared out from these compositions, by means of the single punch laboratory press FROGERAIS AM (SVIAC, Anthony, France).
These tablets had a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1 .35 g/ml ± 0.02 g/ml, and a cylindrical shape with convex faces with a radius of curvature of 13 mm.
The inventors measured the hardness of the tablets thus obtained on an ERWEKA TBH 30 GMD hardness tester (ERWEKA, Heusenstamm, Germany). The value given in Newtons corresponds to a mean value from 1 0 measurements.
EXAMPLE 1 - PREPARATION OF GRANULES OF ALLULOSE ACCORDING TO THE INVENTION USING A BATCH FLUID BED GRANULATOR
Granules of allulose were prepared in a fluid bed granulator Strea-1 (Aeromatic_Fielder / GEA - Bubendorf Switzerland). A solution of allulose is prepared by dissolving 25 g of allulose in 125 ml of water. This solution is sprayed on 300 g of powdery allulose fluidized in the fluid bed granulator. The allulose powder used has a mean diameter of 85 μιτι. The fluidizing air entrance is at 60 °C and the outlet air at 35°C. This solution is added during 1 5 minutes (spraying speed about 1 0 ml per minute). The drying (air at 60 °C) is pursued about 30 minutes after the end of the spraying so that the powder is sufficiently dried. The granules obtained are sieved between 100 μιτι and 1000 μιτι to remove the fine and coarse particles, to give granules [i-A].
EXAMPLE 2 - PREPARATION OF GRANULES OF ALLULOSE ACCORDING TO THE INVENTION USING A ROTATING PAN GRANULATOR Allulose granules were prepared using home-made rotating pan granulator. An allulose solution was prepared by dissolving 450 g of allulose crystal in 50 g water at a temperature of 85 to ~\ 00 °C. The solution was sprayed, with compressed air nozzle, on allulose dry powder in a rotating pan with a ratio of liquid to powder at 1 :4. The liquid spray rate was about 7.5 ml per minute. The liquid temperature was maintained at 90 °C during the process. Granules of allulose of a few millimeters were formed and continuously discharged out of rotating pan while the volume in the pan remains at constant. The granules were dried and maturated at forced-air circulation oven at 75^ for 2 hours and conditioned at ambient temperature for 4 hours. The granules were then grinded and sieved at desired particle size of between 100 and 1000 μιτι to give granules [i-B].
The granules of allulose [i-A] and [i-B] thus obtained were evaluated in compositions for tableting by direct compression, and compared with allulose of prior art obtained by crystallization in water (allulose [c-C]). To this end, tablets were prepared out of these materials, the hardness of which was evaluated according to "Procedure 1 ". Results are showed in Table 1 .
Table 1 : Comparison of the properties of granules of allulose according to the invention with allulose of prior art
Figure imgf000017_0001
These results show that the inventors succeeded for the first time in obtaining a composition comprising high amounts of allulose, which is compressible.
The inventors succeeded for the first time in obtaining directly compressible allulose, allowing the preparation of tablets having hardness greater than 50 N, in the sole presence of a lubricant, in particular in the present case, from compositions composed of 99.0 % by weight of granules of allulose according to the invention and 1 .0 % by weight of magnesium stearate.
The tablets thus obtained exhibited excellent taste and texture. They showed particularly smooth sensation in the mouth when sucking, with no sticking and no gritty sensation, as well as particularly pleasant chewable texture.

Claims

1 . Granules of allulose which are compressible in the sole presence of a lubricant, to form a tablet having a diameter of 13 mm, a thickness of 6 mm, an apparent density of 1 .35 g/ml ± 0.02 g/ml, a cylindrical shape with convex faces with a radius of curvature of 13 mm, whose hardness is greater than 50 N, preferably greater than 60 N, preferably greater than 70 N, preferably greater than 80 N, preferably greater than 90 N, preferably greater than 100 N, even more preferably greater than 1 10 N.
2. Use of the granules of allulose of claim 1 as a direct compression excipient in a directly compressible composition.
3. The use of claim 2, wherein the granules of allulose are further used as a sweetener, and/or a low-calorie sweetener, and/or as a health ingredient having physiological functions such as blood glucose suppressive effect, and/or reactive oxygen species scavenging activity, and/or neuroprotective effect.
4. A directly compressible composition, comprising the granules of allulose of claim 1 .
5. The directly compressible composition of claim 4, wherein said granules of allulose represent at least 30 % of the directly compressible composition, preferably at least 40 %, preferably at least 50 %, preferably at least 60 %, preferably at least 70 %, preferably at least 80 %, preferably at least 90 %, typically between 90 and 99 %, even between 95 and 99 %, said percentage being expressed in dry weight, with respect to the total dry weight of said directly compressible composition.
6. The directly compressible composition according to any one of claims 4 or 5, comprising no more than 60 % of direct compression excipients other than said granules of allulose, preferably no more than 50 %, preferably no more than 40 %, preferably no more than 30 %, preferably no more than 20 %, preferably no more than 10 %, preferably no more than 5 %, more preferably no more than 2 %, and most preferably 0 %, said percentage being expressed in dry weight, with respect to the total dry weight of said directly compressible composition.
7. A method for the manufacture of granules of allulose such as defined in claim 1 , comprising: a step (a) of preparing a granulation liquid comprising allulose;
a step (b) of granulating powdery allulose, by applying the granulation liquid obtained in step (a) onto moving powdery allulose;
a step (c), preferably simultaneous with step (b), of drying the granules obtained in step (b);
an optional step (c') of maturation of the granules obtained in step (c);
a step (d) of recovering the granules obtained in step (c) or (c').
8. A method for the manufacture of a tablet, comprising the steps of: providing a directly compressible composition according to anyone of claims 4 to 6; followed by directly compressing said composition to form the tablet.
9. A tablet composed of a directly compressible composition such as defined in anyone of claims 4 to 6, or obtained by the method of claim 8.
PCT/IB2015/001302 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression WO2016012853A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2955845A CA2955845C (en) 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression
BR112017001000-3A BR112017001000B1 (en) 2014-07-21 2015-07-16 METHOD FOR MANUFACTURING D-ALULOSE GRANULES, D-ALULOSE GRANULES, USE OF SUCH GRANULES, DIRECTLY COMPRESSIBLE COMPOSITION, TABLET AND METHOD FOR MANUFACTURING SUCH TABLET
EP15778703.7A EP3171709A1 (en) 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression
CN201580039976.2A CN106659225B (en) 2014-07-21 2015-07-16 Sugar composition for tabletting by direct compression
MX2017000829A MX2017000829A (en) 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression.
US15/325,030 US20170208849A1 (en) 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression
JP2017503616A JP6731400B2 (en) 2014-07-21 2015-07-16 Sugar composition for tableting by direct compression
SG11201700445YA SG11201700445YA (en) 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression
KR1020177000682A KR102557664B1 (en) 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression
US16/205,696 US11350658B2 (en) 2014-07-21 2018-11-30 Sugar compositions for tableting by direct compression
US17/720,656 US11986002B2 (en) 2014-07-21 2022-04-14 Sugar compositions for tableting by direct compression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306181.0 2014-07-21
EP14306181 2014-07-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/325,030 A-371-Of-International US20170208849A1 (en) 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression
US16/205,696 Division US11350658B2 (en) 2014-07-21 2018-11-30 Sugar compositions for tableting by direct compression

Publications (1)

Publication Number Publication Date
WO2016012853A1 true WO2016012853A1 (en) 2016-01-28

Family

ID=51265637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/001302 WO2016012853A1 (en) 2014-07-21 2015-07-16 Sugar compositions for tableting by direct compression

Country Status (11)

Country Link
US (3) US20170208849A1 (en)
EP (1) EP3171709A1 (en)
JP (1) JP6731400B2 (en)
KR (1) KR102557664B1 (en)
CN (1) CN106659225B (en)
BR (1) BR112017001000B1 (en)
CA (1) CA2955845C (en)
CL (1) CL2017000153A1 (en)
MX (1) MX2017000829A (en)
SG (1) SG11201700445YA (en)
WO (1) WO2016012853A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018127668A1 (en) 2017-01-05 2018-07-12 Roquette Freres Method for producing d-allulose crystals
WO2021219770A1 (en) * 2020-04-30 2021-11-04 Firmenich Sa Flavor particle, its process of manufacture and use for stabilizing flavor

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105148280A (en) * 2015-07-07 2015-12-16 深圳国源国药有限公司 Innovative drug excipient compressible sucrose and preparation method thereof
US10925853B2 (en) * 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
EP4000419A1 (en) * 2020-11-23 2022-05-25 Savanna Ingredients GmbH Drying of allulose crystals

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039813A (en) 1989-06-07 2000-03-21 Xyrofin Oy Fructose-based granulated product and a process for the production thereof
EP1538200A1 (en) * 2002-05-22 2005-06-08 Fushimi Pharmaceutical Company, Limited Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide
WO2005060937A1 (en) * 2003-12-23 2005-07-07 Chr. Hansen A/S Compressed tablets comprising viable probiotic microorganisms
JP2005263670A (en) 2004-03-17 2005-09-29 Kagawa Univ Crystal of l-psicose, method for producing the same, and saccharide reagent kit
EP1905442A1 (en) * 2005-07-20 2008-04-02 Teikoku Seiyaku Co., Ltd. Utilization of anti-neuropathic pain effect of d-allose and d-psicose
US20090304891A1 (en) 2006-11-10 2009-12-10 Matsutani Chemical Industry Co., Ltd. Sweetener containing d-psicose and foods and drinks obtained by using the same
EP2156751A1 (en) 2007-05-18 2010-02-24 Matsutani Chemical Industry Co., Ltd. Novel sweetener having sugar-like taste and production method and use of the same
US20120076908A1 (en) 2010-09-29 2012-03-29 Matsutani Chemical Industry Co., Ltd. Composition for improving taste of high-intensity sweetener and application thereof
WO2014175119A1 (en) 2013-04-26 2014-10-30 松谷化学工業株式会社 Agent or method for treatment and/or prevention of accelerated energy expenditure and/or diminished energy expenditure functionality

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3305447A (en) 1963-06-12 1967-02-21 American Sugar Tabletting sugar and method of preparing same
US3627583A (en) 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
US4698101A (en) * 1982-08-30 1987-10-06 Suomen Sokeri Oy (Finnish Sugar Company Ltd.) Binder-diluent composition and method
DE60036205T2 (en) 2000-07-27 2008-05-21 Roquette Frères Granules consisting of starch and lactose
EP1757297B1 (en) 2004-05-26 2013-11-13 National University Corporation Kagawa University COMPOSITION FOR treating ARTERIOSCLEROSIS IN DIABETIC PATIENTS
EP1864669B1 (en) * 2005-03-23 2018-06-27 Rare Sugar Production Technical Research Laboratories, LLC Application of d-psicose to suppression of abnormal circadian increase in blood glucose level
KR101373591B1 (en) 2006-11-17 2014-03-12 마쓰다니가가꾸고오교가부시끼가이샤 Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm
FR2925499B1 (en) * 2007-12-20 2010-02-12 Roquette Freres MALTITOL GRANULE FOR DIRECT COMPRESSION AND PROCESS FOR PREPARING THE SAME
JP6216493B2 (en) 2011-06-24 2017-10-18 国立大学法人 香川大学 Life extender
CN102697744B (en) * 2012-05-29 2013-11-27 安吉东来药用辅料有限责任公司 Allose tablet excipient, medicinal tablet and method for preparing medicinal tablet

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039813A (en) 1989-06-07 2000-03-21 Xyrofin Oy Fructose-based granulated product and a process for the production thereof
EP1538200A1 (en) * 2002-05-22 2005-06-08 Fushimi Pharmaceutical Company, Limited Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide
WO2005060937A1 (en) * 2003-12-23 2005-07-07 Chr. Hansen A/S Compressed tablets comprising viable probiotic microorganisms
JP2005263670A (en) 2004-03-17 2005-09-29 Kagawa Univ Crystal of l-psicose, method for producing the same, and saccharide reagent kit
EP1905442A1 (en) * 2005-07-20 2008-04-02 Teikoku Seiyaku Co., Ltd. Utilization of anti-neuropathic pain effect of d-allose and d-psicose
US20090304891A1 (en) 2006-11-10 2009-12-10 Matsutani Chemical Industry Co., Ltd. Sweetener containing d-psicose and foods and drinks obtained by using the same
EP2156751A1 (en) 2007-05-18 2010-02-24 Matsutani Chemical Industry Co., Ltd. Novel sweetener having sugar-like taste and production method and use of the same
US20120076908A1 (en) 2010-09-29 2012-03-29 Matsutani Chemical Industry Co., Ltd. Composition for improving taste of high-intensity sweetener and application thereof
WO2014175119A1 (en) 2013-04-26 2014-10-30 松谷化学工業株式会社 Agent or method for treatment and/or prevention of accelerated energy expenditure and/or diminished energy expenditure functionality
EP2992887A1 (en) 2013-04-26 2016-03-09 Matsutani Chemical Industry Co., Ltd. Agent or method for treatment and/or prevention of accelerated energy expenditure and/or diminished energy expenditure functionality

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUO, J-H.: "Lactose in Pharmaceutical Applications", DRUG DEVELOPMENT & DELIVERY, 27 March 2008 (2008-03-27), XP055404791, Retrieved from the Internet <URL:http://www.drug-dev.com/Main/Back-Issues/Lactose-in-Pharmaceutical-Applications-466.aspx>
MU ET AL.: "Recent advances on applications and biotechnological production of D-psicose", APPL. MICROBIOL. BIOTECHNOL., vol. 94, 2012, pages 1461 - 1467, XP035060669
TOUSEY, M. D.: "The Granulation Process 101 - Basic Technologies for Tablet Making", PHARMACEUTICAL TECHNOLOGY: TABLETING & GRANULATION, 2002, pages 8 - 13, XP002976643

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018127668A1 (en) 2017-01-05 2018-07-12 Roquette Freres Method for producing d-allulose crystals
US11945835B2 (en) 2017-01-05 2024-04-02 Roquette Freres Method for producing D-allulose crystals
WO2021219770A1 (en) * 2020-04-30 2021-11-04 Firmenich Sa Flavor particle, its process of manufacture and use for stabilizing flavor

Also Published As

Publication number Publication date
BR112017001000A2 (en) 2017-11-14
CL2017000153A1 (en) 2017-07-28
CN106659225B (en) 2021-04-02
BR112017001000B1 (en) 2021-11-30
US20220240560A1 (en) 2022-08-04
EP3171709A1 (en) 2017-05-31
SG11201700445YA (en) 2017-02-27
MX2017000829A (en) 2017-05-01
US20170208849A1 (en) 2017-07-27
CA2955845A1 (en) 2016-01-28
JP6731400B2 (en) 2020-07-29
US11986002B2 (en) 2024-05-21
US11350658B2 (en) 2022-06-07
US20190090528A1 (en) 2019-03-28
KR102557664B1 (en) 2023-07-20
JP2017522032A (en) 2017-08-10
KR20170030524A (en) 2017-03-17
CA2955845C (en) 2022-08-16
CN106659225A (en) 2017-05-10

Similar Documents

Publication Publication Date Title
US11986002B2 (en) Sugar compositions for tableting by direct compression
CA2955849C (en) Sugar compositions for tableting by direct compression
JP3649742B2 (en) Sugar-free sugar coating products
AU7652300A (en) Method for producing a tablet made of isomaltulose, isomalt or isolmalt variants
JP2001504687A (en) Compressed composition comprising a sweetener mixture
RU2222224C2 (en) Raw material for pressed product adaptable for direct pressing process
KR20090067100A (en) Granulated maltitol for direct compression and method of preparation thereof
EP3202405A1 (en) Oligosaccharide preparation and method for manufacturing same
JP4847862B2 (en) Tablet containing branched-chain amino acid and method for producing the same
JP4980597B2 (en) Solids containing processed kuzuhana
EP2467027B1 (en) Process for compressing isomalt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15778703

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15325030

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20177000682

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/000829

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2955845

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2015778703

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015778703

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017503616

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017001000

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017001000

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170117